Jacobs Levy Equity Management’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Jacobs Levy Equity Management’s Portfolio SCMP Stock Details SCMP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-26,670	Closed	-$315K	–	1124
2017 Q3	$315K	Buy	+26,670	New	+$299K	0.01%	785
2016 Q3	–	Sell	-36,800	Closed	-$404K	–	1217
2016 Q2	$404K	Sell	36,800 -92,890	-72%	-$1.04M	0.01%	814
2016 Q1	$1.42M	Buy	+129,690	New	+$1.64M	0.03%	489
2015 Q4	–	Sell	-23,213	Closed	-$461K	–	919
2015 Q3	$461K	Sell	23,213 -2,580	-10%	-$59.1K	0.01%	591
2015 Q2	$424K	Sell	25,793 -5,400	-17%	-$93.6K	0.01%	596
2015 Q1	$485K	Sell	31,193 -7,609	-20%	-$118K	0.01%	583
2014 Q4	$554K	Buy	+38,802	New	+$410K	0.01%	592
2014 Q2	–	Sell	-101,156	Closed	-$723K	–	987
2014 Q1	$723K	Buy	101,156 +34,456	+52%	+$295K	0.01%	608
2013 Q4	$627K	Sell	66,700 -24,900	-27%	-$178K	0.01%	669
2013 Q3	$572K	Sell	91,600 -43,100	-32%	-$269K	0.01%	655
2013 Q2	$886K	Buy	+134,700	New	+$1.07M	0.02%	597

Other funds holding SCMP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

Krensavage Asset Management New York $263M AUM 66.99% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Jacobs Levy Equity Management's SCMP Position: Q4 2017 in Review

Jacobs Levy Equity Management sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q4 2017, closing a stake of 26,670 shares — an estimated $315K sold.

Jacobs Levy Equity Management first reported a position in SCMP in Q2 2013 and held it in 11 quarters. The position peaked at $1.42M in Q1 2016. 188 funds tracked by Wall St. Rank hold SCMP as of Q4 2017.

Jacobs Levy Equity Management reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
Jacobs Levy Equity Management sold 26,670 Sucampo Pharmaceuticals, Inc. shares in Q4 2017, an estimated $315K.
Jacobs Levy Equity Management first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 11 quarters.
Jacobs Levy Equity Management's Sucampo Pharmaceuticals, Inc. position peaked at $1.42M in Q1 2016.
188 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q4 2017.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2017, filed 13 Feb 2018.